A biotech start-up company supported by SUNY Downstate Medical Center’s Biotech Incubator has created a revolutionary new process for conditioning patients to receive bone marrow transplantation. In recognition of its technological advances, HemoGenyx is now the only Brooklyn-based company publicly listed on the London Stock Exchange.

While at the biotechnology incubator, HemoGenyx developed bi-specific antibodies for preparing patients for bone marrow transplantation making the process less invasive and safer than traditional chemotherapy and radiation treatments. This new process may be used to increase success of bone marrow transplantation as a method to treat blood diseases such as leukemia, lymphoma, multiple myeloma, and diseases of the immune system.

“Downstate’s Biotech Incubator provides medical and research facilities where small companies can flourish right here in Brooklyn while tapping into local assets affording growth into independent businesses with significant impact in health care,” said SUNY Downstate President Dr. Wayne J. Riley. “We are very proud of HemoGenyx’s efforts in improving health care for patients across the world, and look forward to new start-ups joining our community, diversifying local industries, and boosting our local economy.”

As part of SUNY Downstate’s Biotechnology Initiative, the biotechnology incubator offers start-up biotech companies space and resources near the Downstate campus. Participants have access to Downstate Medical Center resources including clinical scientists and PhD students, the medical and scientific library, clinical trials, and specialized research facilities and equipment.

“The SUNY Downstate Biotech Incubator provided the high-quality facility we needed for the life sciences research that led to this treatment breakthrough,” said Dr. Vladislav Sandler, the founder of HemoGenyx, LLC. “Instead of focusing on pulling together all the resources needed for this important research, our team was able to rely on SUNY Downstate, its facilities, and its experts to create a safer approach to bone marrow transplants.”